Verrica Pharmaceuticals Inc (NASDAQ: VRCA) kicked off on Monday, down -5.64% from the previous trading day, before settling in for the closing price of $0.76. Over the past 52 weeks, VRCA has traded in a range of $0.70-$11.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -13.60%. While this was happening, its average annual earnings per share was recorded -3.55%. With a float of $49.03 million, this company’s outstanding shares have now reached $90.56 million.
Let’s determine the extent of company efficiency that accounts for 100 employees. In terms of profitability, gross margin is 72.9%, operating margin of -815.5%, and the pretax margin is -922.81%.
Verrica Pharmaceuticals Inc (VRCA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verrica Pharmaceuticals Inc is 45.86%, while institutional ownership is 15.81%. The most recent insider transaction that took place on Aug 26 ’24, was worth 69,647. In this transaction CHIEF LEGAL OFFICER of this company sold 26,183 shares at a rate of $2.66, taking the stock ownership to the 115,303 shares. Before that another transaction happened on Aug 27 ’24, when Company’s CHIEF LEGAL OFFICER sold 9,530 for $2.46, making the entire transaction worth $23,444. This insider now owns 105,773 shares in total.
Verrica Pharmaceuticals Inc (VRCA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.55% per share during the next fiscal year.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
Take a look at Verrica Pharmaceuticals Inc’s (VRCA) current performance indicators. Last quarter, stock had a quick ratio of 1.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.83, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -0.68 in one year’s time.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Looking closely at Verrica Pharmaceuticals Inc (NASDAQ: VRCA), its last 5-days average volume was 0.5 million, which is a jump from its year-to-date volume of 0.49 million. As of the previous 9 days, the stock’s Stochastic %D was 6.18%. Additionally, its Average True Range was 0.13.
During the past 100 days, Verrica Pharmaceuticals Inc’s (VRCA) raw stochastic average was set at 0.51%, which indicates a significant decrease from 5.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 107.28% in the past 14 days, which was lower than the 161.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1653, while its 200-day Moving Average is $4.6644. However, in the short run, Verrica Pharmaceuticals Inc’s stock first resistance to watch stands at $0.7833. Second resistance stands at $0.8485. The third major resistance level sits at $0.8982. If the price goes on to break the first support level at $0.6684, it is likely to go to the next support level at $0.6187. Should the price break the second support level, the third support level stands at $0.5535.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Key Stats
The company with the Market Capitalisation of 61.65 million has total of 45,601K Shares Outstanding. Its annual sales at the moment are 5,120 K in contrast with the sum of -67,000 K annual income. Company’s last quarter sales were recorded 5,180 K and last quarter income was -17,190 K.
